Radiopharmaceutical company Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) announced on Wednesday that it will present 20 company-related abstracts at the 39th European Association of Nuclear Medicine (EANM) Annual Congress in Vienna from 17 to 21 October 2026, highlighting clinical trials and next-generation theranostics for prostate, brain and kidney cancers.

Key presentations include Phase 3 results from the IPAX BrIGHT trial of TLX101-Tx in recurrent glioblastoma and the LUTEON trial of TLX250-Tx in clear cell renal cell carcinoma, alongside interim results from the PTherpan-Lu trial of TLX597-Tx in metastatic prostate cancer. Topline Phase 3 data for TLX591-Px prostate cancer imaging in Chinese men and real-world findings for TLX250-Px in kidney cancer will also be presented.

The programme includes research from Telix's targeted alpha therapy and medical technology programmes, covering imaging, dosimetry software and artificial intelligence. The company will also host a symposium on advances in theranostics for urological cancers on 18 October.

Telix will showcase its Illuccix prostate cancer imaging agent, therapeutic pipeline and technologies, including the SENSEI miniature gamma probe and QDOSE dosimetry software.